O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate → HCID 58386737, 화합물
반응식
[O:1]=[C:2]1[N:8]([CH:9]2[CH2:14][CH2:13][N:12]([C:15]3[N:20]=[CH:19][N:18]=[C:17]([C:21](O)=[O:22])[CH:16]=3)[CH2:11][CH2:10]2)[CH2:7][CH2:6][C:5]2[CH:24]=[CH:25][CH:26]=[CH:27][C:4]=2[NH:3]1.[NH:28]1[C:38]2[C:39]3[CH:30]([CH2:31][C:32](=[O:40])[NH:33][C:34]=3[CH:35]=[CH:36][CH:37]=2)[CH2:29]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F>CN(C=O)C>[O:1]=[C:2]1[NH:3][C:4]2[CH:27]=[CH:26][CH:25]=[CH:24][C:5]=2[CH2:6][CH2:7][N:8]1[CH:9]1[CH2:14][CH2:13][N:12]([C:15]2[N:20]=[CH:19][N:18]=[C:17]([C:21]([N:28]3[C:38]4[C:39]5[CH:30]([CH2:31][C:32](=[O:40])[NH:33][C:34]=5[CH:35]=[CH:36][CH:37]=4)[CH2:29]3)=[O:22])[CH:16]=2)[CH2:11][CH2:10]1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
63mg (0.17 mmol) 6-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid and 30 mg (0.17 mmol) 1,2,2a,5-tetrahydro-3H-pyrrolo-[4,3,2-de]quinolin-4-one in 56 μL (0.40 mmol) TEA and 1.8 mL DMF were mixed with 58 mg (0.18 mmol) TBTU and the mixture was stirred overnight at RT. Then the reaction mixture was purified by preparative HPLC-MS. The product-containing fractions were combined and freeze-dried.
후처리
- customThen the reaction mixture was purified by preparative HPLC-MS
- customfreeze-dried
출처 및 근거
- ORD 기록
- ord-e3864c8e1a2644cf9abd6589fdc61f5f
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08829006B2
반응 노트
불러오는 중…